MedTrace Logo

JT001 (VV116) for the Treatment of COVID-19

NCT05582629 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1369

Last updated 2023-06-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of JT001 (VV116) in participants with mild to moderate COVID-19.

Conditions

  • Mild to Moderate COVID-19

Interventions

DRUG

JT001

JT001 administered orally in tablet form every 12 hours for 5 days

DRUG

Placebo

Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days

Sponsors & Collaborators

  • Sponsor GmbH

    collaborator OTHER

  • Shanghai Vinnerna Biosciences Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-21
Primary Completion
2023-02-14
Completion
2023-02-14

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05582629 on ClinicalTrials.gov